SCHEMBL4575173

SCHEMBL4575173

COc1ccc(CCNc2ccc(C)cn2)cc1

nearest known ligand 0.64

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.61
CYP3A4 P08684 2/20 0.60
CYP1A2 P05177 2/20 0.60
CYP2D6 P10635 2/20 0.60
CYP2C9 P11712 2/20 0.60
CYP2C19 P33261 2/20 0.60
HTT P42858 2/20 0.60
SMN1; SMN2 Q16637 2/20 0.60
HDAC1 Q13547 1/20 0.53
LMNA P02545 1/20 0.49
TP53 P04637 1/20 0.49
PTGDR Q13258 6/20 0.48
ABL1 P00519 1/20 0.48
RIN1 Q13671 1/20 0.48
NPC1 O15118 2/20 0.47
RAB9A P51151 1/20 0.47
KMT2A Q03164 1/20 0.47
TSHR P16473 2/20 0.47
GALR3 O60755 1/20 0.45
ALDH1A1 P00352 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11563180 0.88 ALDH1A1 (0.51) MAPTCYP3A4CYP1A2CYP2D6CYP2C9
SCHEMBL3669945 0.85 NPC1 (0.63) MAPTHDAC1LMNANPC1RAB9A
SCHEMBL12832040 0.82 SMN1; SMN2 (0.63) MAPTHTTSMN1; SMN2LMNATP53
SCHEMBL11561635 0.81 RAB9A (0.63) MAPTSMN1; SMN2LMNANPC1RAB9A
SCHEMBL11559612 0.80 HDAC1 (0.65) CYP3A4CYP1A2CYP2D6CYP2C9CYP2C19
SCHEMBL4574800 0.78 SMN1; SMN2 (0.59) MAPTCYP3A4CYP1A2CYP2D6CYP2C9
SCHEMBL3249345 0.78 SMN1; SMN2 (0.62) MAPTCYP3A4CYP1A2CYP2D6CYP2C9
SCHEMBL4574655 0.78 CYP1A2 (0.66) MAPTCYP3A4CYP1A2CYP2D6CYP2C9
SCHEMBL6645913 0.77 MAPT (0.53) MAPTSMN1; SMN2LMNARAB9AKMT2A
SCHEMBL6681204 0.76 MAPT (1.00) MAPTCYP3A4CYP1A2CYP2D6CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100273780-A1 SUBSTITUTED 8-HETEROARYL XANTHINES PGXHEALTH, LLC (US) 2010-10-28 US disclosed
US-20100273780-A1 SUBSTITUTED 8-HETEROARYL XANTHINES PGXHEALTH, LLC (US) 2010-10-28 US disclosed
US-7732455-B2 Substituted 8-heteroaryl xanthines PGX HEALTH, LLC (US) 2010-06-08 US disclosed
US-7732455-B2 Substituted 8-heteroaryl xanthines PGX HEALTH, LLC (US) 2010-06-08 US disclosed
US-20080200456-A1 Substituted 8-Heteroaryl Xanthines ALLERGAN SALES, LLC 2008-08-21 US disclosed
US-20080200456-A1 Substituted 8-Heteroaryl Xanthines ALLERGAN SALES, LLC 2008-08-21 US disclosed
US-7342006-B2 Substituted 8-heteroaryl xanthines ADENOSINE THERAPEUTICS, LLC (US) 2008-03-11 US disclosed
US-7342006-B2 Substituted 8-heteroaryl xanthines ADENOSINE THERAPEUTICS, LLC (US) 2008-03-11 US disclosed
US-7319104-B2 hPPARs activators SMITHKLINE BEECHAM CORPORATION (US) 2008-01-15 US disclosed
US-7319104-B2 hPPARs activators SMITHKLINE BEECHAM CORPORATION (US) 2008-01-15 US disclosed
US-7319104-B2 hPPARs activators SMITHKLINE BEECHAM CORPORATION (US) 2008-01-15 US disclosed
US-20050137212-A1 Hppars activators SMITHKLINE BEECHAM CORPORATION 2005-06-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080200456-A1 Substituted 8-Heteroaryl Xanthines ADORA2B, ADORA2A, ADORA3 MAPT 4665/4885CYP3A4 520/4885CYP1A2 203/4885
US-20050137212-A1 Hppars activators PPARG, PPARA, PPARD MAPT 3860/4885CYP3A4 372/4885CYP1A2 668/4885
US-20100273780-A1 SUBSTITUTED 8-HETEROARYL XANTHINES ADORA2B, ADORA2A, ADORA3 MAPT 4665/4885CYP3A4 520/4885CYP1A2 203/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.